Clinical trials: Metastasis Colorectal Cancer
Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung…
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02888743
- Testing
- Durvalumab, Radiation Therapy, Tremelimumab
- Where
- 42 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, oxaliplatin, capecitabine, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT01280643
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Gastrointestinal Cancer
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Research has shown that anti-angiogenic agents can be effective therapies to treat cancer. Anti-angiogenic agents target the blood vessels required for tumors to grow.
- Trial name
- NCT01058655
- Testing
- Everolimus, Tivozanib
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Dana-Farber Cancer Institute
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667)…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer
- Trial name
- ARROW (NCT03037385)
- Testing
- pralsetinib (BLU-667)
- Where
- 71 sites in United States, Belgium and 11 more
- Volunteers
- 590 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
The primary objective of the Phase II portion of this study is to assess the efficacy of KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)/CapOx (capecitabine…
- Trial name
- NCT00838578
- Testing
- KRN330, Irinotecan
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Metastatic Colorectal Cancer
A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
This is an open label, single-arm, Phase 2 trial to evaluate the anti-tumor activity, safety, and tolerability of Pembrolizumab in combination with azacitidine in subjects with chemo-refractory mCRC without any further standard…
- Trial name
- NCT02260440
- Testing
- Pembrolizumab, Azacitidine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Anuradha Krishnamurthy
Metastatic Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
The purpose of this study is to evaluate the efficacy and safety of selinexor alone or with pembrolizumab in participants with advanced or metastatic colorectal cancer (CRC).
- Trial name
- NCT04854434
- Testing
- Selinexor, Pembrolizumab, Trifluridine
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Karyopharm Therapeutics Inc
Solid Tumor
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
This was an open-label, nonrandomized, Phase 1/2 study designed to determine the safety, tolerability, and efficacy of epacadostat when given in combination with pembrolizumab and 7 different chemotherapy regimens described as…
- Trial name
- NCT03085914
- Testing
- Epacadostat, Pembrolizumab, Oxaliplatin
- Where
- 16 sites in United States
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Metastatic Colorectal Carcinoma
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI.
- Trial name
- NCT01937715
- Testing
- PF-05212384, FOLFIRI regimen, Bevacizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 18 people
- Sponsor
- Pfizer
Metastatic Gastric Cancer, Metastatic Breast Cancer
Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
The purpose of this clinical study is to assess the safety and tolerability and efficacy of active immunotherapy with dose escalation and cohort expansion of OBI-833 in advanced/metastatic gastric, lung, colorectal, or breast…
- Conditions
- Metastatic Gastric Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Lung Cancer
- Trial name
- NCT02310464
- Testing
- OBI-833/OBI-821
- Where
- 4 sites in Taiwan
- Volunteers
- 25 people
- Sponsor
- OBI Pharma, Inc
Colorectal Cancer, Squamous Cell Head and Neck Cancer
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
- Conditions
- Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT01451632
- Testing
- MM-121, Irinotecan, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Merrimack Pharmaceuticals
Colorectal Cancer
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line…
- Trial name
- NCT00069095
- Testing
- Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg
- Where
- 236 sites in United States, Australia and 31 more
- Volunteers
- 2,035 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
This single arm study will evaluate the efficacy and safety of a first-line regimen of Avastin and XELOX (oxaliplatin + Xeloda) in patients with metastatic cancer of the colon or rectum.
- Trial name
- NCT00577031
- Testing
- bevacizumab [Avastin], Oxaliplatin, Xeloda
- Where
- 38 sites in Italy
- Volunteers
- 205 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer
The purpose of this study is to assess the safety and clinical activity of the experimental drug EMD 525797 (study drug), a monoclonal antibody targeting alfa integrins, in combination with irinotecan and cetuximab in K-ras…
- Trial name
- POSEIDON (NCT01008475)
- Testing
- EMD 525797 250 mg, EMD 525797 500 mg, EMD 525797 750 mg
- Where
- 62 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 232 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Solid Tumor
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
- Trial name
- LODESTAR (NCT04171700)
- Testing
- Rucaparib
- Where
- 19 sites in United States
- Volunteers
- 83 people
- Sponsor
- pharmaand GmbH
Colorectal Neoplasms, Neoplasm Metastasis
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
The main objective of the study was to evaluate the effectiveness of aflibercept (versus placebo) in increasing the overall survival in participants with metastatic colorectal cancer treated with FOLFIRI (Irinotecan…
- Trial name
- VELOUR (NCT00561470)
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- Where
- 221 sites in United States, Argentina and 26 more
- Volunteers
- 1,226 people
- Sponsor
- Sanofi
Colorectal Cancer
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic…
- Trial name
- NCT02788279
- Testing
- Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib
- Where
- 73 sites in United States, Australia and 9 more
- Volunteers
- 363 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasms
Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
The purpose of this clinical trial is to determine whether it is safe to treat patients with advanced colorectal cancer, with humanised A33 antibody tagged with radioactive iodine (131I-huA33) in combination with chemotherapy…
- Trial name
- NCT00291486
- Testing
- Capecitabine, 131I-huA33 (131-Iodine on humanised monoclonal antibody A33)
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Ludwig Institute for Cancer Research
Colon Cancer, Colorectal Cancer
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer.
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT00630786
- Testing
- Panitumumab, Conatumumab
- Volunteers
- 53 people
- Sponsor
- Amgen
Colorectal Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
RATIONALE: Vaccines made from a gene-modified virus and a person's white blood cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00103142
- Testing
- falimarev, inalimarev, sargramostim
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Michael Morse, MD